KR102272744B1 - 에스.아우레우스 연관 질병의 치료 방법 - Google Patents

에스.아우레우스 연관 질병의 치료 방법 Download PDF

Info

Publication number
KR102272744B1
KR102272744B1 KR1020207024078A KR20207024078A KR102272744B1 KR 102272744 B1 KR102272744 B1 KR 102272744B1 KR 1020207024078 A KR1020207024078 A KR 1020207024078A KR 20207024078 A KR20207024078 A KR 20207024078A KR 102272744 B1 KR102272744 B1 KR 102272744B1
Authority
KR
South Korea
Prior art keywords
ser
gly
thr
val
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207024078A
Other languages
English (en)
Korean (ko)
Other versions
KR20200102533A (ko
Inventor
브렛 셀만
크리스틴 트카지크
멜리사 해밀턴
레이 후아
Original Assignee
메디뮨 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 엘엘씨 filed Critical 메디뮨 엘엘씨
Priority to KR1020217020104A priority Critical patent/KR20210083389A/ko
Publication of KR20200102533A publication Critical patent/KR20200102533A/ko
Application granted granted Critical
Publication of KR102272744B1 publication Critical patent/KR102272744B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020207024078A 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법 Active KR102272744B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217020104A KR20210083389A (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261723128P 2012-11-06 2012-11-06
US61/723,128 2012-11-06
KR1020157011460A KR20150092738A (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법
PCT/US2013/068385 WO2014074470A1 (en) 2012-11-06 2013-11-05 Methods of treating s. aureus-associated diseases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157011460A Division KR20150092738A (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217020104A Division KR20210083389A (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법

Publications (2)

Publication Number Publication Date
KR20200102533A KR20200102533A (ko) 2020-08-31
KR102272744B1 true KR102272744B1 (ko) 2021-07-06

Family

ID=50685101

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020157011460A Ceased KR20150092738A (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법
KR1020207024078A Active KR102272744B1 (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법
KR1020217020104A Ceased KR20210083389A (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020157011460A Ceased KR20150092738A (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217020104A Ceased KR20210083389A (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법

Country Status (13)

Country Link
US (3) US9845348B2 (enExample)
EP (1) EP2928490B1 (enExample)
JP (2) JP6506172B2 (enExample)
KR (3) KR20150092738A (enExample)
CN (2) CN112316135A (enExample)
AU (2) AU2013341421A1 (enExample)
BR (1) BR112015010126B1 (enExample)
CA (1) CA2890385C (enExample)
ES (1) ES2912267T3 (enExample)
MX (1) MX367082B (enExample)
RU (1) RU2661406C2 (enExample)
SG (2) SG10201703677VA (enExample)
WO (1) WO2014074470A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2708977C2 (ru) 2011-06-10 2019-12-12 МЕДИММЬЮН, ЭлЭлСи Молекулы, связывающиеся с psl pseudomonas, и пути их применения
BR112014011028B1 (pt) 2011-11-07 2021-03-02 Medimmune, Llc anticorpo biespecífico, composição, e, uso da composição
MX367082B (es) * 2012-11-06 2019-08-05 Medimmune Llc Anticuerpos anti toxina alfa de s. aureus (anti-ta) y sus usos.
EP2917360B1 (en) * 2012-11-06 2020-01-08 Medlmmune, LLC Antibodies to s. aureus surface determinants
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
CA3107463A1 (en) 2018-07-24 2020-01-30 Medimmune, Llc Antibody directed against s. aureus clumping factor a (clfa)
BR112021006704A2 (pt) 2018-10-09 2021-08-10 Medimmune, Llc anticorpos dirigidos contra leucotoxinas de staphylococcus aureus
TW202035443A (zh) 2018-10-09 2020-10-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌抗體的組合
JP7682795B2 (ja) 2019-03-13 2025-05-26 メディミューン，エルエルシー コロニー形成患者における黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）感染症の低減
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007145689A1 (en) 2006-06-12 2007-12-21 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
EP2453881A2 (en) * 2009-07-16 2012-05-23 Georgia Health Sciences University Research Institute, Inc. Porous-wall hollow glass microspheres as carriers for biomolecules
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
HRP20182017T4 (hr) 2011-02-08 2021-08-20 Medimmune, Llc Protutijela koja specifično vežu alfa toksin koji stvara staphylococcus aureus i postupci uporabe
JP2014507142A (ja) * 2011-02-08 2014-03-27 インテグレイテッド バイオセラピューティクス，インコーポレイテッド α溶血素オリゴペプチドを含む免疫原性組成物
MX367082B (es) * 2012-11-06 2019-08-05 Medimmune Llc Anticuerpos anti toxina alfa de s. aureus (anti-ta) y sus usos.
EP2917360B1 (en) 2012-11-06 2020-01-08 Medlmmune, LLC Antibodies to s. aureus surface determinants
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2017075188A2 (en) 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody

Also Published As

Publication number Publication date
EP2928490A1 (en) 2015-10-14
JP2019142888A (ja) 2019-08-29
KR20150092738A (ko) 2015-08-13
CA2890385C (en) 2022-07-12
AU2018236849A1 (en) 2018-10-18
CN104780934A (zh) 2015-07-15
MX367082B (es) 2019-08-05
CN112316135A (zh) 2021-02-05
WO2014074470A1 (en) 2014-05-15
US9845348B2 (en) 2017-12-19
US10457724B2 (en) 2019-10-29
AU2018236849B2 (en) 2020-05-21
EP2928490B1 (en) 2022-03-30
KR20200102533A (ko) 2020-08-31
MX2015005481A (es) 2016-01-14
RU2661406C2 (ru) 2018-07-16
RU2015121617A (ru) 2016-12-27
CA2890385A1 (en) 2014-05-15
JP6926138B2 (ja) 2021-08-25
AU2013341421A1 (en) 2015-06-04
JP6506172B2 (ja) 2019-04-24
US20190002540A1 (en) 2019-01-03
US10759849B2 (en) 2020-09-01
BR112015010126B1 (pt) 2022-11-01
BR112015010126A2 (enExample) 2017-08-22
SG10201703677VA (en) 2017-06-29
US20160257733A1 (en) 2016-09-08
EP2928490A4 (en) 2016-11-02
JP2015536951A (ja) 2015-12-24
US20200109191A1 (en) 2020-04-09
HK1215173A1 (zh) 2016-08-19
ES2912267T3 (es) 2022-05-25
KR20210083389A (ko) 2021-07-06
SG11201503231YA (en) 2015-05-28

Similar Documents

Publication Publication Date Title
KR102272744B1 (ko) 에스.아우레우스 연관 질병의 치료 방법
KR102288394B1 (ko) 스타필로코커스 아우레우스 표면 결정인자에 대한 항체
US20150044168A1 (en) Treatment of Multiple Sclerosis With Anti-CD19 Antibody
JP2022512647A (ja) 抗黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）抗体の組み合わせ
HK1215173B (en) Methods of treating s. aureus-associated diseases
US20240109961A1 (en) Treatment of chronic prurigo
TW202511292A (zh) 用於治療ＮＳＣＬＣ及ｃＨＬ之ＰＤ－１／ＴＩＭ－３結合蛋白
TW202506180A (zh) 用於癌症治療之pd-1/tigit結合蛋白
RU2808018C2 (ru) Антитела к поверхностным детерминантам s. aureus
WO2025250726A1 (en) Anti-kit antibody dosing and methods
CN119654169A (zh) 抗体-药物缀合物和双特异性检查点抑制剂的组合
CN117120089A (zh) 慢性痒疹的治疗
HK1215452B (zh) 金黃色葡萄球菌表面決定簇的抗體

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200820

Application number text: 1020157011460

Filing date: 20150430

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200917

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201205

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210329

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210628

Application number text: 1020157011460

Filing date: 20150430

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210629

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210630

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240522

Start annual number: 4

End annual number: 4